Align Summit: Allston based KiraGen Bio is aiming to program CAR-T cells to tune out the suppressive nature of the tumor micro environment. The first program will be for GBM.
Co-Founder and CEO Aaron Edwards describes the rational behind this approach, as opposed charging the cells with cytokines or removing their brakes. He also explains why KiraGen is looking abroad to do its first clinical trials.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.